{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-088710","form_type":"8-K","ticker":"GUTS","cik":"0001572616","company_name":"FRACTYL HEALTH, INC.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.835595+00:00","generated_at":"2026-05-18T23:41:11.386968+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fractyl Health: Revita shows 92% weight maintenance post-GLP-1; Rejuva prevents obesity in mice","bullets":["12 of 13 Revita participants maintained or lost weight at 3 months after stopping GLP-1; median weight stable (0.46% change).","No serious adverse events with Revita; REMAIN-1 Midpoint cohort data expected Q3 2025 and Pivotal cohort H2 2026.","Rejuva single dose prevented obesity and hyperglycemia in high-fat diet mice; 20% weight reduction and 38% glucose decrease.","Rejuva RJVA-001 progressing toward first-in-human studies; preliminary clinical data anticipated in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-088710","json":"https://secwatch.observer/filing/0000950170-25-088710.json","markdown":"https://secwatch.observer/filing/0000950170-25-088710.md","text":"https://secwatch.observer/filing/0000950170-25-088710.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1572616/000095017025088710/0000950170-25-088710-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1572616/000095017025088710/guts-20250623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:41:11.386968+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}